NCT00637884View on ClinicalTrials.gov

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms

PHASE4CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

February 29, 2004

Conditions

Cat Induced Allergic Rhinitis

Interventions

DRUG

Fexofenadine HCl

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00637884 - A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms | Biotech Hunter | Biotech Hunter